March 18, 2022
1 min watch
Save
VIDEO: Recent developments in treatment of metastatic triple-negative breast cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Kevin Kalinsky, MD, discussed recent developments in the treatment of metastatic triple-negative breast cancer presented at 39th Miami Breast Cancer Conference.
"We reiterated the point that for patients who are newly diagnosed with metastatic triple-negative breast cancer that it is critical to check for PDL1 positivity," Kalinsky, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, said , noting that the only FDA-approved checkpoint inhibitor for these patients is pembrolizumab (Keytruda, Merck).
Published by:
Sources/Disclosures
Collapse
Disclosures:
Kalinsky reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.